Britain and America have agreed to a important trade agreement that will guarantee zero tariffs on British medicine products entering the American market.
The Terms of the Accord
As part of the deal, the UK has agreed to boost spending on medicines through the public health system. This commitment guarantees that tariffs on these key exports will be held at nothing for a period of three years.
This development is in response to recent warnings to dramatically increase duties on patented drug products, with figures discussed up to double the cost.
"This deal between the United Kingdom bolsters the global environment for new treatments and brings much-needed balance to American-British medicine commerce," an announcement noted.
Trade Significance
Drugs are one of the the United Kingdom's biggest exports to the America, which is clearly the primary market for large companies like GSK and AstraZeneca.
Export figures reveal that in the year to the end of last September, the UK sold pharmaceutical products totaling billions to the US. This value represented nearly one-fifth of total UK exports in that period.
"This guarantee protects jobs, stimulates capital expenditure and sets the stage for the UK to establish itself as a worldwide center for medical research," the Business and Trade Secretary commented.
Detailed British Pledges
The agreement involves several notable pledges from the UK:
- Higher Cost Ceiling: The UK will increase the price threshold at which it judges new treatments to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a target to increase total NHS spending on treatments from 0.3 percent of GDP to 0.6% over the next decade.
- Payback Limit: The amount manufacturers must refund to the NHS to stay within budget will be capped at fifteen percent. In the past, refunds exceeded twenty percent.
Recent Tensions
The deal comes amid a protracted tension between the drug companies and the UK government over spending levels and NHS adoption.
These tensions were heightened by arguments that US customers were paying significantly more for the same drugs than people in the other developed nations.
Recently, several major drug company projects in the UK have been delayed or scrapped, while substantial investments have been directed toward US facilities.
One official publicly accepted that the NHS needed to invest a greater share on drugs, noting that its budget allocation on drugs had declined as a percentage of its total funding over the past decade.
